BioProcess Technology Consultants

QUOTES OF NOTE

“BioProcess Technology Consultants has provided expert technical advice and CMC project management for MGI's plasmid DNA development programs — Amolimogene and ZYC300. We look forward to continuing to work with BioProcess Technology Consultants as we continue toward pivotal trials and commercialization for these very important molecules.”
Mary Lynne Hedley, SVP and CSO
Mike Jarpe, VP, Pharmaceutical Development
MGI Pharma, Inc.

“BioProcess Technology Consultants served as a consultant to one of our clients concerning CMC issues. With their outstanding industry experience BPTC made a major contribution to the project. Not only did they facilitate the steering of the project efficiently they also helped to find straightforward solutions to problems always keeping regulatory requirements in mind. In fact BPTC was not 'just a consultant' but an integral part of an excellent team.”
Dr. Thomas Maier, Managing Director
Wacker Biotech, a division of Wacker Chemie AG

“As with leveraging the experience of an established biopharmaceutical CMO, your project benefits from BPTC with their strong industrial background, broad network, focused and knowledgeable approach—not only time-wise, but especially cost-wise. The added value lies in an accelerated time to market.”
Sven Frie
Head of Project Evaluation
Global Microbial Operations Lonza AG
Lonza AG

“Bioprocess Technology Consultants have been long-time supporters of programs in the IBC Biopharmaceutical Production Series. As advisors, chairpersons and speakers at many IBC conferences, their knowledge of the industry always helps raise the quality of our programs. We can always count on them for a broad, unbiased perspective on industry challenges and trends.”
Ellen C. King, Head, Bioprocessing Series,
IBC Life Sciences

“BioProcess Technology Consultants provided invaluable help in the development of our lead product TT-103. Their experience and professionalism helped our Company detect deficiencies and solve them in an efficient and timely manner that resulted in significant cost savings. We would not hesitate to contract BPTC’s services in future projects.”
Luis Caveda, Ph.D.
Executive Vice President
Thrombotargets, Inc.

"BioProcess Technology Consultants' rapid, professional response and broad experience base enabled Cubist to finish our due diligence on a product in-licensing opportunity in a timely manner and to complete a value-added product acquisition. BioProcess Technology Consultants worked closely with our team to completely analyze all aspects of the product development and manufacturing plans, and continued to play important roles in our development activities after in-licensure.”
Timothy Keutzer, Director, Project Management
Cubist Pharmaceuticals, Inc.

“BioProcess Technology Consultants has provided Millennium Pharmaceuticals with expert technical advice on several biopharmaceutical development programs, including our current lead candidate MLN0002. We look forward to continuing to work with BioProcess Technology Consultants as we move toward pivotal trials and commercialization for this first in class molecule.”
Michael Glacken, Director, Biologics Process Development
Millennium Pharmaceuticals, Inc.

“BioProcess Technology Consultants has provided leadership, insight, expert technical advice, and efficient program management of all CMC activities for CBL’s lead biopharmaceutical development program for CBLB502. We look forward to continuing to work with BioProcess Technology Consultants as we continue the development of this highly potent and effective radioprotectant.”
Farrell Fort
Vice President, Drug Development
Cleveland BioLabs

“Over the years, SangStat Medical Corporation has utilized the excellent services of Howard Levine, and his organization. Dr. Levine has traveled to several overseas manufacturing locations as a SangStat consultant, and has been able to quickly and accurately identify problem situations and develop corrective actions, which were expeditiously implemented. His assistance in one instance enabled us to keep our flagship product on the market, in the face of manufacturing issues.”
Ralph Levy
President REL Consulting
Former President, Osel Inc.
Former Executive Vice President, SangStat Medical Corporation (now a division of Genzyme Corporation)